Francisco Borrego
Francisco Borrego
BioCruces Health Research Institute, Ikerbasque Basque Foundation for Science
Dirección de correo verificada de
TítuloCitado porAño
Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence–derived peptides by CD94/NKG2 confers protection from natural …
F Borrego, M Ulbrecht, EH Weiss, JE Coligan, AG Brooks
Journal of Experimental Medicine 187 (5), 813-818, 1998
Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells
F Borrego, J Kabat, DK Kim, L Lieto, K Maasho, J Peña, R Solana, ...
Molecular immunology 38 (9), 637-660, 2002
NK phenotypic markers and IL2 response in NK cells from elderly people
F Borrego, MC Alonso, MD Galiani, J Carracedo, R Ramirez, B Ostos, ...
Experimental gerontology 34 (2), 253-265, 1999
NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor
AG Brooks, PE Posch, CJ Scorzelli, F Borrego, JE Coligan
Journal of Experimental Medicine 185 (4), 795-800, 1997
Cutting edge: NKG2D is a costimulatory receptor for human naive CD8+ T cells
K Maasho, J Opoku-Anane, AI Marusina, JE Coligan, F Borrego
The Journal of Immunology 174 (8), 4480-4484, 2005
CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor
F Borrego, MJ Robertson, J Ritz, J Pena, R Solana
Immunology 97 (1), 159, 1999
Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells
AG Brooks, F Borrego, PE Posch, A Patamawenu, CJ Scorzelli, ...
The Journal of Immunology 162 (1), 305-313, 1999
US Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
RA de Claro, K McGinn, V Kwitkowski, J Bullock, A Khandelwal, ...
Clinical Cancer Research 18 (21), 5845-5849, 2012
IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells
SJ Burgess, AI Marusina, I Pathmanathan, F Borrego, JE Coligan
The Journal of Immunology 176 (3), 1490-1497, 2006
The CD94/NKG2 family of receptors
F Borrego, M Masilamani, AI Marusina, X Tang, JE Coligan
Immunologic research 35 (3), 263-277, 2006
The CD300 molecules: an emerging family of regulators of the immune system
F Borrego
Blood, The Journal of the American Society of Hematology 121 (11), 1951-1960, 2013
The NKG2D receptor: immunobiology and clinical implications
SJ Burgess, K Maasho, M Masilamani, S Narayanan, F Borrego, ...
Immunologic research 40 (1), 18-34, 2008
Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system™
K Maasho, A Marusina, NM Reynolds, JE Coligan, F Borrego
Journal of immunological methods 284 (1-2), 133-140, 2004
Peptides isolated from HLA-Cw* 0304 confer different degrees of protection from natural killer cell-mediated lysis
F Zappacosta, F Borrego, AG Brooks, KC Parker, JE Coligan
Proceedings of the National Academy of Sciences 94 (12), 6313-6318, 1997
Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells
VR Simhadri, JF Andersen, E Calvo, SC Choi, JE Coligan, F Borrego
Blood 119 (12), 2799-2809, 2012
CD94/NKG2A inhibits NK cell activation by disrupting the actin network at the immunological synapse
M Masilamani, C Nguyen, J Kabat, F Borrego, JE Coligan
The Journal of Immunology 177 (6), 3590-3596, 2006
Regulation of CD69 expression on human natural killer cells: differential involvement of protein kinase C and protein tyrosine kinases
F Borrego, J Peña, R Solana
European journal of immunology 23 (5), 1039-1043, 1993
The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition
LC Sullivan, CS Clements, T Beddoe, D Johnson, HL Hoare, J Lin, ...
Immunity 27 (6), 900-911, 2007
Role of regulator of G protein signaling 16 in inflammation-induced T lymphocyte migration and activation
E Lippert, DL Yowe, JA Gonzalo, JP Justice, JM Webster, ER Fedyk, ...
The Journal of Immunology 171 (3), 1542-1555, 2003
Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective
C Eguizabal, O Zenarruzabeitia, J Monge, S Santos, MA Vesga, N Maruri, ...
Frontiers in immunology 5, 439, 2014
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20